{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk+Non-Muscle-Invasive+Bladder+Cancer&page=2",
    "query": {
      "condition": "High-Risk Non-Muscle-Invasive Bladder Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk+Non-Muscle-Invasive+Bladder+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:50:36.754Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06833073",
      "title": "A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms",
        "Non-Muscle Invasive Bladder Neoplasms",
        "Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 308,
      "start_date": "2025-03-11",
      "completion_date": "2031-09-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 20,
      "location_summary": "Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06833073"
    },
    {
      "nct_id": "NCT03091660",
      "title": "S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage 0 Bladder Urothelial Carcinoma",
        "Stage 0is Bladder Urothelial Carcinoma",
        "Stage I Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "BCG Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG Tokyo-172 Strain Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG Tokyo-172 Strain Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2017-02-24",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 174,
      "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03091660"
    },
    {
      "nct_id": "NCT05943106",
      "title": "BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Muscle- Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-08-11",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05943106"
    },
    {
      "nct_id": "NCT02143804",
      "title": "Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "High Grade",
        "Non Muscle Invasive"
      ],
      "interventions": [
        {
          "name": "oncolytic adenovirus expressing GMCSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-03",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143804"
    },
    {
      "nct_id": "NCT04640623",
      "title": "A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAR-200",
          "type": "DRUG"
        },
        {
          "name": "Cetrelimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2020-12-18",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sherman Oaks, California + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640623"
    },
    {
      "nct_id": "NCT04387461",
      "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CG0070",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "n-dodecyl-B-D-maltoside",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2020-12-08",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Orange, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387461"
    },
    {
      "nct_id": "NCT02030574",
      "title": "Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Bladder Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine and fractionated cisplatin (combination treatment)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2014-07",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-08-24",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02030574"
    },
    {
      "nct_id": "NCT03258593",
      "title": "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Vicineum",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "Bladder Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Urine cytology",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Electrocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2018-06-07",
      "completion_date": "2022-10-17",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03258593"
    },
    {
      "nct_id": "NCT04564781",
      "title": "Predicting BCG Response",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 400,
      "start_date": "2020-09-18",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04564781"
    },
    {
      "nct_id": "NCT02015104",
      "title": "Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PANVAC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-12-18",
      "completion_date": "2019-05-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-05-22T04:50:36.754Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02015104"
    }
  ]
}